Gtlf3b Inhibitors
Chemical inhibitors of Gtlf3b function primarily through the disruption of the cell cycle by targeting cyclin-dependent kinases (CDKs), which are crucial in the regulation of cell cycle progression. Alsterpaullone, Kenpaullone, Indirubin-3'-monoxime, Roscovitine, Olomoucine, Flavopiridol, Butyrolactone I, Purvalanol A, Dinaciclib, and AZD5438 are molecules that inhibit various CDKs, thus preventing the phosphorylation of proteins that are essential for cells to progress through different stages of the cell cycle. This inhibition can lead to cell cycle arrest, during which Gtlf3b function is indirectly inhibited because its activity is likely tied to the cell cycle's precise regulation. For example, Alsterpaullone and Kenpaullone are known to inhibit CDKs, which would prevent the phosphorylation and subsequent activation of proteins necessary for the cell cycle to proceed, effectively arresting the cycle at a point where Gtlf3b is not needed.
Continuing with this theme, compounds like Roscovitine and Olomoucine offer more selective inhibition of CDKs, such as CDK1, CDK2, and CDK3. The specificity of Flavopiridol and Butyrolactone I towards several CDKs also results in a blockade of the cell cycle, thereby inhibiting the functionality of Gtlf3b. Similarly, Purvalanol A's inhibition of CDK1, CDK2, and CDK5 leads to a disruption of the cell cycle, which is expected to inhibit Gtlf3b function. Dinaciclib, a potent inhibitor of CDKs, affects the cell cycle in a way that is likely to lead to Gtlf3b inhibition. Lastly, AZD5438's inhibition of CDK1, CDK2, and CDK9 can result in cell cycle arrest, thus indirectly inhibiting Gtlf3b function if it is involved in cell cycle-regulated processes. Ribociclib's action on CDK4/6 further underscores the relationship between cell cycle control and Gtlf3b activity, as its inhibition of these kinases can disrupt the G1-S phase transition, a critical point where Gtlf3b function can be regulated.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a known inhibitor of cyclin-dependent kinases (CDKs). By inhibiting CDKs, it prevents the phosphorylation of proteins required for cell cycle progression, which can lead to the inhibition of Gtlf3b function, as Gtlf3b activity is tied to the cell cycle. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Kenpaullone, another CDK inhibitor, operates similarly to Alsterpaullone by preventing the phosphorylation of cell cycle proteins, potentially leading to the inhibition of Gtlf3b by stalling the cell cycle at a point where Gtlf3b function is not required. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
This molecule is an inhibitor of various kinases including CDKs. By inhibiting these kinases, it can block the phosphorylation state of proteins involved in the cell cycle, subsequently inhibiting Gtlf3b function which is dependent on the cell cycle phase. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine selectively inhibits CDKs, which are critical for the regulation of the cell cycle. Inhibition of these kinases can lead to cell cycle arrest, which can indirectly inhibit Gtlf3b activity, as it may be functionally active in specific cell cycle phases. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective inhibitor of CDKs, particularly CDK1, CDK2, and CDK3. Inhibition of these kinases can disrupt the cell cycle, potentially leading to an indirect inhibition of Gtlf3b, which may require an active cell cycle for its function. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits several CDKs, leading to cell cycle arrest. As Gtlf3b activity is potentially linked to cell cycle progression, flavopiridol can indirectly inhibit Gtlf3b by disrupting its associated cell cycle-dependent processes. | ||||||
Butyrolactone I | 87414-49-1 | sc-201533 sc-201533A | 200 µg 1 mg | $122.00 $514.00 | 1 | |
Butyrolactone I is a selective inhibitor of CDK2. By inhibiting CDK2, it can impede the progression of the cell cycle, potentially leading to the functional inhibition of Gtlf3b, which may rely on cell cycle progression for its activity. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A inhibits CDKs, particularly CDK1, CDK2, and CDK5, leading to disruption of the cell cycle. This disruption is likely to inhibit the function of Gtlf3b indirectly, as it may be dependent on cell cycle progression for its activity. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent inhibitor of CDKs, affecting the cell cycle and potentially leading to the inhibition of Gtlf3b, which may interact with proteins that are regulated by the cell cycle. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 is an inhibitor of CDK1, CDK2, and CDK9 which may lead to cell cycle arrest and thereby inhibit the function of Gtlf3b if it is involved in cell cycle-regulated processes. | ||||||